- Home
- HMST vs DBVT Comparison
HMST vs DBVT Comparison
Compare HMST & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMST
- DBVT
- Stock Information
- Founded
- HMST 1921
- DBVT 2002
- Country
- HMST United States
- DBVT France
- Employees
- HMST N/A
- DBVT N/A
- Industry
- HMST Major Banks
- DBVT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HMST Finance
- DBVT Health Care
- Exchange
- HMST Nasdaq
- DBVT Nasdaq
- Market Cap
- HMST 211.3M
- DBVT 239.9M
- IPO Year
- HMST 2012
- DBVT N/A
- Fundamental
- Price
- HMST $13.03
- DBVT $8.35
- Analyst Decision
- HMST Hold
- DBVT Buy
- Analyst Count
- HMST 3
- DBVT 4
- Target Price
- HMST $14.17
- DBVT $14.81
- AVG Volume (30 Days)
- HMST 77.5K
- DBVT 102.2K
- Earning Date
- HMST 07-28-2025
- DBVT 07-29-2025
- Dividend Yield
- HMST N/A
- DBVT N/A
- EPS Growth
- HMST N/A
- DBVT N/A
- EPS
- HMST N/A
- DBVT N/A
- Revenue
- HMST $78,454,000.00
- DBVT $3,497,000.00
- Revenue This Year
- HMST $161.80
- DBVT $1,700.53
- Revenue Next Year
- HMST $8.90
- DBVT $535.67
- P/E Ratio
- HMST N/A
- DBVT N/A
- Revenue Growth
- HMST N/A
- DBVT N/A
- 52 Week Low
- HMST $8.09
- DBVT $2.21
- 52 Week High
- HMST $16.10
- DBVT $12.78
- Technical
- Relative Strength Index (RSI)
- HMST 65.81
- DBVT 42.98
- Support Level
- HMST $12.18
- DBVT $8.33
- Resistance Level
- HMST $12.76
- DBVT $9.92
- Average True Range (ATR)
- HMST 0.49
- DBVT 0.92
- MACD
- HMST 0.01
- DBVT -0.32
- Stochastic Oscillator
- HMST 92.42
- DBVT 4.53
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.
About DBVT DBV Technologies S.A.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.